

Enamel-Related Gene Products in Calvarial Development

Phimon Atsawasuwan^{1,2}, Xuanyu Lu¹, Yoshihiro Ito¹, Yinghua Chen², Gokul
Gopinathan¹, Carla A. Evans², Ashok B. Kulkarni⁴, Carolyn W. Gibson⁵,
Xianghong Luan^{1,2,3}, and Thomas G.H. Diekwisch^{1,2,3*}

¹Brodie Laboratory for Craniofacial Genetics, University of Illinois at Chicago, Illinois
USA 60612

²Department of Orthodontics, University of Illinois at Chicago, Illinois, USA 60612

³UIC Department of Oral Biology, College of Dentistry, Illinois USA 60612

⁴National Institute for Dental and Craniofacial Research, National Institutes of Health,
Bethesda, MD, USA

⁵Department of Anatomy and Cell Biology, University of Pennsylvania School of Dental
Medicine, Philadelphia, PA, USA

*Corresponding author:

Tom Diekwisch, Professor and Head,
Department of Oral Biology
University of Illinois at Chicago College of Dentistry
801 S Paulina St., Chicago, Illinois, USA 60612
Telephone: (312) 996-7505
Email address: tom¹dkw@uic.edu

ABSTRACT

Enamel-related gene products (ERPs) are detected in non-enamel tissues such as bone. We hypothesized that if functional, ERP expression corresponds with distinct events during osteoblast differentiation and affects bone development and mineralization. In mouse calvariae and MC3T3 cells, expression profiles of enamel-related gene products (ERPs) correlated with key events in postnatal calvarial development and MC3T3 cell mineralization. Developing skulls from both *Amel*- and *Ambn*-deficient animals were approximately 15% shorter when compared to wild-type controls, and their sutures remained patent for a longer period of time. Analysis of *Amel*- and *Ambn*-deficient calvaria and calvarial osteoblast cultures revealed a dramatic reduction in mineralized nodules, a significant reduction in *Runx2*, *Sp7*, *Ibsp*, and *Msx2* expression, and a reduction in *Alx4* in *Amel*-deficient calvariae versus an increase in *Alx4* in *Ambn*-deficient calvariae. Together, these data indicate that ERP expression follows defined developmental profiles and affects osteoblast differentiation, mineralization, and calvarial bone development. We propose that in parallel to their role in the developing enamel matrix, ERPs have retained an evolutionary conserved function related to the biomineralization of bones.

KEY WORDS: enamel; amelogenin; ameloblastin; osteoblast; calvaria

INTRODUCTION

The mineralized tissues bone, dentin, cementum and tooth enamel play quintessential roles in the life of organisms, acting as guardians of the brain and powerful effectors of mastication. Their formation and maintenance is tightly controlled by several phosphorylated and repeat-element containing matrix proteins, which are encoded by a cluster of secretory phosphoprotein encoding genes (SCPP) located on chromosome 4 (Huq et al., 2005). One half of these proteins are associated with the formation of bone & dentin, counting bone sialoprotein (BSP), osteopontin (OPN), dentin sialophosphoprotein (DSPP), dentin matrix protein (DMP), and matrix-extracellular phosphoglycoprotein (MEPE) among its members. The other half consists of the enamel-associated proteins ameloblastin (AMBN), enamelin (ENAM), amelotin (AMTN), and odontogenic ameloblast-associated protein (ODAM). Besides their affiliation with the same gene cluster, SCPP proteins contain a number of sequence elements including internal repeats, acidity of select domains, phosphorylation, and negative charge that predispose them to promote mineral nucleation through calcium ion sequestration, or control crystal growth by adsorption onto growing crystal surfaces, or both (Addison and McKee, 2010).

The first study pointing to common gene products in enamel and other mineralized tissues was based on a monoclonal antibody generated against a hamster tooth germ (Inai et al., 1993). Subsequently, other studies have blurred the distinction between enamel-type and bone/dentin-type mineralized tissues, highlighting expression of amelogenin (Amel) in dentin, cementum, periodontal

ligament, long bone, brain and soft tissues (Deutsch et al., 2006; Haze et al., 2007; Li et al., 2006; Ye et al., 2006; Zeichner-David et al., 2006) and Ambn expression in dentin, cementum, pulp and cranial bones (Fong et al., 1998; Hao et al., 2005; Nunez et al., 2010; Spahr et al., 2002).

The ubiquitous expression of SCPPs in multiple mineralized tissues in conjunction with similar but distinct functions suggests that SCPP proteins collaborate to control and fine-tune the growth of craniofacial mineralized tissues. Here we have conducted studies to define the role of ERPs in craniofacial mineralized tissue development. First, ERP expression in calvarial bone and tooth enamel development was mapped and correlated with key events in calvarial mineralization. To test the role of two key ERPs in osteogenesis, the effects of AMBN and AMEL on mineralization markers, mineral formation, and calvarial development were determined using a diet-independent cell culture model in tandem with mutant mouse models. Together these studies provide a re-evaluation of the roles of ERPs in mineralized tissue development.

MATERIALS AND METHODS

Animals and cell culture

Postnatal CD1 mice age 3, 10, 20, and 35 days ($n = 48$)(Charles River Laboratories, Wilmington, MA), as well as B6;129 wildtype, *Amelx*^{-/-} (Gibson et al., 2001) and *Ambn*^{-/-} ($n=48$) (Fukumoto et al., 2004) stage-matched mice were handled in accordance with the UIC Use of Animals in Research protocol. Mouse calvaria-derived MC3T3-E1 cells (CRL-2593) subclone 4 were maintained in α -minimum essential medium (Gibco BRL, Gaithersburg, MD). Primary calvarial osteoblasts were obtained from calvariae of P1 mice (*Amelx*^{-/-}, *Ambn*^{-/-}, Wildtype). For osteoinduction, primary calvarial cells were cultured onto 6-well culture plates containing Dulbecco's modified eagle's medium (Gibco BRL) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 50 μ g/ml of ascorbic acid and 3 μ M of beta-glycerophosphate.

Alcian blue/alizarin red staining

Three CD1 mice per time point (P3-35), and P2 B6;129 and ERP mutant mice were fixed and dehydrated with ethanol and acetone, stained with alcian blue and alizarin red S for 2 d, immersed in 0.5% potassium hydroxide solution, and stored in 80% glycerol.

RT-realtime PCR

Total mRNA was extracted from calvariae and molars of CD 1 mice at pre-determined developmental stages or MC3T3 cells after 7, 14, 28, and 42 days

culture in mineralization medium. To quantify mRNA expression levels, RT-realtime PCR was performed using sequence specific Sybergreen primers (Appendix Table 1) and ABI Prism 7000 detection system (Applied Biosystems, Carlsbad, CA). Samples were normalized using β -actin. Relative expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method (Livak and Schmittgen, 2001). For mRNA expression studies, day 0 in culture and P3 in calvariae were used as baseline (=1) and β -actin was used as an endogenous control, and all PCR products were sequenced at the UIC DNA facility for sequence verification.

Immunohistochemistry

Calvarial vaults from CD1 mouse heads at age P6 were fixed, decalcified, paraffin-embedded and sectioned. Sections were processed and incubated with ERP protein primary antibodies (Appendix, Table 2) at a 1:50 dilution as reported (Lu et al., 2013).

Western blot analysis

Calvariae from CD1 mice aged P2, P10 and P20 were ground under liquid N₂. Aliquots of calvarial protein extracts were subjected to Western blotting (primary antibody dilutions listed in Appendix, Table 2). Tooth proteins from extracted maxillary molars of P3 mice were used as positive controls.

***In vitro* mineralization assay**

In vitro mineralization assays (alizarin red) were performed on MC3T3

cultures just before the medium was switched to mineralization medium (wk 0) and at each subsequent interval (wk 1, 2, 4 and 6).

Statistical analyses

Analyses were performed in triplicate for three independent experiments. Kruskal Wallis analysis of variance was used to determine the mean difference, and Independent T test were used to determine the pair-difference at $P = 0.05$.

Results

Enamel-related gene products (ERPs) expression in mouse calvariae

To determine whether occurrences of ERPs in tissues outside of enamel follow concise developmental patterns, longitudinal ERP expression levels were mapped in correlation with calvarial development stages from day P3-P35 (Fig. 1A). The bony bridge of the posterior frontal suture began to form in P20 animals and completely closed on day 35 (Fig. 1A). mRNA expression levels of ERPs, *Amel*, *Ambn*, *Enam*, *Amtn*, *Odam*, *Mmp20*, and *Klk4*, were detected in calvarial tissues at all stages of development. During calvarial development, ERP profiles changed substantially (Fig. 1B), and expression of ERPs gradually decreased from P3 to P35, with the exception of *Ambn* and *MMP20*, which peaked at P20 and then decreased gradually.

MC3T3 pre-osteoblasts proliferate, differentiate into osteoblasts, and exhibit signs of mineralization in long-term cell culture (Quarles et al. 1992). Here we have used the MC3T3 long-term cell culture model to ask the question whether ERPs display specific expression profiles during osteoblast differentiation and mineralization. RT-realtime PCR analysis indicated that all studied ERPs (*Amel*, *Ambn*, *Enam*, *Amtn*, *Odam*), as well as the enzymes *Mmp20* and *Klk4* were expressed during the entire 42 days of culture. To compare ERP expression profiles with key stages of MC3T3-related mineral formation and osteoblast differentiation in culture, mineralization levels were assessed using an *in vitro* mineralization assay (Fig. 1C), and benchmarks of osteoblast differentiation were identified using *Col1A1*, *Ibsp*, and *Ocn* mRNA

expression levels as reference points (Fig. 1E). ERPs exhibited distinct expression patterns and profile changes during key stages of matrix mineralization and differentiation of MC3T3 cells (Figs. 1D). Specifically, Amel and Mmp20 expression profiles revealed a bi-phasic pattern (Fig. 1D), corresponding to the onset of mineralization and the peak expression of Col1A1 and Ibsp (28 days of culture, Figs. 1D,E). In contrast, Ambn, Amtn, Odam and Klk4 expression levels peaked at day 7 (Fig. 1D) corresponding with the early differentiation of MC3T3 cells (Fig. 1C), and then gradually decreased. Data are from three independent studies, which yielded essentially identical findings.

Immunohistochemistry and Western blotting of ERPs in developing calvariae

Amelogenins make up 90% of the enamel protein matrix whereas collagen 1a1 contributes 90% of the bone protein matrix. To determine whether ERPs contribute significantly to the non-collagenous calvarial bone protein matrix, ERP protein and mRNA expression levels in developing mouse calvariae and teeth were compared. First, Amel, Ambn and Enam were immunohistochemically detected in calvarial tissues from P6, mainly in the bone matrix and periosteum (Fig. 2A, right panel). Weak levels of reactivity were also documented in osteoblasts, osteocytes and periosteal cells (Fig. 2A, right panel). Amel, Ambn and Enam were localized in ameloblasts and enamel matrices (Fig 2A, left panel). Using Western blotting, all three ERPs (Amel, Ambn, Enam) were detected in P3, P10, and P20 calvariae as well as T3 teeth, with the exception of Amel in P20 calvariae (Fig. 2B). Protein levels for all three, Amel, Ambn, and

Enam, were higher in P3 calvariae than in calvariae of later stages of postnatal development, while ERP levels in T3 teeth exceeded those found in P3 calvariae by approximately 60-1000 folds (calculated after taking the 1:20-1:40 pre-dilution of enamel proteins in this Western blot into account, Fig. 2B). RT-realtime PCR teeth/calvariae expression comparisons revealed high ERP levels in 3dpn teeth when compared to calvariae, with higher *Amtn*, *Klk4*, *Odam* and *Amel* expression levels in calvariae than other ERPs (Fig. 2C).

Amel and Ambn affect developing skull size and suture closure

In developing calvarial bone matrices and cultured MC3T3 cells, ERP levels were well beyond detection threshold, stage-specific, and time-dependent. These findings prompted us to determine whether the loss of key ERPs in calvarial cells would affect skull growth (Fig. 3). Phenotype penetrance was 100%, and an interfrontal bone in *Amel*-deficient mice was present in 40% of the animals. Both skull length and width of P2 *Ambn*- and the *Amel*-deficient mice were significantly reduced compared to wild-type controls (16.2% *Ambn*^{-/-} and 13.4% *Amel*^{-/-} length reduction, $P < 0.05$; Fig. 3A,B). Moreover, suture closure was delayed in *Ambn*- and *Amel*-deficient animals (Fig. 3C) and an interfrontal bone was frequently found between the frontal bones of *Amel*-deficient mice (Fig. 3D). The interfrontal suture remained patent in 60 dpn in *Amel*^{-/-} and *Ambn*^{-/-} mice, and frontal bone length in *Amel*^{-/-} mice was substantially reduced (Fig. 3E).

Effect of Amel and Ambn on osteoblast differentiation

To ask whether changes in skull size and mineralization were directly affected by ERP function and independent from feeding behavior in ERP mutant mice, osteoblast mineralization and key mineralization marker gene expression were assayed. There was a significant reduction of *Ibsp* mRNA expression in *Ame1*-deficient calvariae while *Sp7* was reduced in *Ambn*-deficient calvariae when compared to calvarial mRNA of wildtype littermates ($P < 0.05$, Fig. 4A and B). There was a highly significant 5-10 fold reduction in *Runx2*, *Sp7*, and *Ibsp* bone marker mRNA expression levels in *Ame1*-deficient calvarial osteoblasts ($P < 0.05$, Fig. 4C) and a highly significant approximately 50% reduction in *Runx2*, *Sp7*, and *Ibsp* expression in *Ambn*-deficient calvarial osteoblasts ($P < 0.05$, Fig. 4D). The suture-patency related transcription factor *Msx2* was reduced in calvariae of both *Ame1*- and *Ambn*-deficient mice, while *Alx4* was reduced in *Ame1*-deficient mice and increased in *Ambn*-deficient mice. *Twist1* was only reduced in *Ambn*-deficient mice while *Fgfr2* was increased in *Ame1*-deficient mice and not in *Ambn*-deficient mice (Fig. 4B and C). Mineral nodule formation in *Ame1*- and *Ambn*-deficient calvarial osteoblasts after 4-week culture was severely reduced (Fig. 4G).

Discussion

The present study was designed to address three aspects about the presence of ERPs in tissues outside of enamel: (i) ERP expression levels in bone, (ii) correlation of ERPs in developing calvarial bone and in differentiating pre-osteoblasts with key events in mineralization and differentiation, and (iii) effect of calvarial osteoblast ERPs on mineralization behavior and bone marker gene expression (Diekwisch, 2011). To address these questions, ERP expression levels in developing MC3T3 cells and calvarial osteoblasts were assessed and compared with ERP expression levels in developing tooth enamel. To ask whether ERPs were of functional relevance for bone development, osteoblasts from wildtype and *Amel*^{-/-} and *Ambn*-deficient mice were cultured and examined for mineralization potential and bone marker gene expression. In addition, skulls of *Amel*^{-/-} and *Ambn*-deficient mice were analyzed.

Our study revealed that all ERPs studied here were detected in calvarial tissues and MC3T3 cells, and appeared to correlate with key time points in osteoblast differentiation and mineralization. ERP expression patterns in MC3T3 osteoblast long-term culture peaked either at day 7 (*Ambn*, *Enam*, *Amtn*, *Odam* and *Klk4*) or at day 28 (*Amel* and *Mmp20*). Based on parallel studies, these time points correlated with either the early differentiation of osteoblasts as indicated by a rise in *Col1*, *Ibsp*, and *Ocn* at day 7 or with the beginning of matrix mineralization at day 28. These data indicate that *Ambn*, *Enam*, *Amtn*, and *Odam* expression peaks are functionally correlated with events in osteoblast differentiation, while *Amel* might play a role in bone matrix mineralization.

According to our immunoreactions, ERPs were not only detected in the bone matrix but also in the surrounding periosteum, suggesting that they might affect calvarial growth on both locations.

In response to the question about functional relevance of ERP expression in calvarial osteoblasts, our study revealed that a number of bone-related parameters were significantly reduced in both *Amel*- and *Ambn*-deficient models when compared to wildtype controls, including (i) *Runx2*, *Sp7*, and *Ibsp* expression levels, (ii) osteoblast mineral nodule formation, and (iii) size of developing calvariae and suture closure. Together, these findings illustrate that both *Amel* and *Ambn* ERPs exhibit highly visible effects on bone matrix mineralization and bone marker gene expression. The concept that ERPs are involved in osteoblast differentiation or bone matrix mineralization is supported by a number of previous studies related to the role of *Amel* in the modulation of mineralized tissue homeostasis, including activation of osteoclastogenesis (Hatakeyama et al., 2006), modulation of cementogenesis (Swanson et al., 2006), and bone marrow stem cell proliferation (Huang et al., 2010). Recent studies suggested that *Ambn* binds CD63, and may act through integrin β 1 and C Src kinase inhibition to promote osteogenic differentiation (Iizuka et al., 2011), (Zhang et al., 2011). Unique dysregulation profiles of major suture-patency regulating genes such as *Msx2*, *Twist1*, *Alx4* and *Fgfr2* (Melville et al., 2010) in *Amel*- versus *Ambn*-deficient mice suggest that individual ERPs affect individual transcription factor cascades to affect downstream effects on suture morphogenesis.

Five of the ERPs gene studied here, *Ambn*, *Enam*, *Amtn*, *Odam* and *Amel*, are members of the secretory calcium-binding phosphoprotein (SCPP) gene cluster of evolutionarily related skeletal mineralization molecules (Kawasaki and Weiss, 2008). According to our analysis, individual ERPs displayed 20-40% similarity with other SCPP family members, and bone proteins such as IBSP and OPN had more negatively charged amino acid residues than ERPs, suggesting that bone proteins may play a greater role in the regulation of crystal growth regulation (nucleation and/or inhibition) than ERPs. However, based on their sequence homologies, expression pattern overlap, and functional similarities, we suggest that all SCPP-derived proteins including ERPs contribute to the functional complexities of developing bone and other mineralized tissues. Evidence presented in this paper indicates that even after acquiring novel functions in enamel matrix organization, ERPs have retained their functional significance in bone development and homeostasis. Recent reports have shown a molecular decay of enamel matrix protein genes in turtles and other edentulous amniotes (Meredith et al., 2013). These data suggest that the presence of enamel proteins in bone and other mineralized tissues may not be essential for the survival of organisms, but simply fine-tune the biochemical make-up of the mineralization scaffold of bones in tooth-bearing vertebrates.

ACKNOWLEDGEMENTS

This study was supported by NIDCR grants DE18057, DE19155 to XL, DE18900 to TGHD, and the Thomas M Graber AAOF fellowship to PA. No conflicts of interest are reported.

Figure legends

Figure 1. Expression profiles of enamel-related gene products (ERPs) correlated with postnatal calvarial development and MC3T3 cell mineralization. **(A)** mouse calvariae visualized by Alcian blue/Alizarin Red S staining. The red staining in calvarial preparations represents developing calvarial mineralized tissues. ERP mRNA expression relative to endogenous control (β -actin) mRNA was detected at all stages of development and levels of most ERPs with the exception of *Ambn* gradually decreased with animal age **(B)**. **(C)** Alizarin red *in vitro* mineralization assay illustrating stages of mineralization during MC3T3-E1 cell culture over a period of 42 days. **(D)** Time course of ERP mRNA expression levels relative to β -actin in MC3T3-E1 cells as revealed by real-time RT-PCR. **(E)** Matched Real-time RT-PCR analysis of bone marker mRNA expression levels relative to β -actin.

Figure 2. ERP expression comparison between postnatal developing tooth organs and calvariae. **(A)** Positive immunoreaction (red color) for amelogenin (*Amel*), ameloblastin (*Ambn*), and enamelin (*Enam*) in ameloblasts, enamel matrix, bone matrix and periosteum. Scale = 100 μ m. **(B)** Western blot detection of amelogenin (*Amel*), ameloblastin (*Ambn*), and enamelin (*Enam*) in calvarial bone extracts at postnatal days 3, 10 and 20 and in developing tooth organs at postnatal day 3. Note that in this figure tooth extracts were diluted at a 1:20 ratio (*Ambn* and *Enam*) or a 1:40 ratio (*Amel*) dilution relative to calvarial extracts to visualize expression levels on the same blot. **(C)** Relative ERP mRNA expression levels between developing calvariae and teeth at postnatal day 3 and 10. Δ Ct were normalized to beta actin and $\Delta\Delta$ Ct was performed to calculate fold change in expression values relative to wild-type calvaria. si = stratum intermedium, amel = ameloblasts, en = enamel, de = dentin, od = odontoblasts, p = periosteum, b = bone, ob = osteoblasts.

Figure 3. Comparison of skull dimensions and features between *Ambn* deficient (*Ambn* KO), wild-type (WT), and amelogenin deficient (*Amel* KO) mice. **(A)** whole skull comparison between representative skulls, **(B)** length and width comparison between *Ambn* KO, *Amel* KO, and WT mice, **(C)** calvarial vaults after removal of the cranial base, **(D)** pronounced interfrontal bone (*Os frontale*) in *Amel* deficient mice, **(E)** frontal suture patency in *Amel* KO, *Ambn* KO, and WT mice. * = $P < 0.05$

Figure 4. Bone transcription factor and marker expression and mineralization levels in calvariae and calvarial osteoblasts from ERP mutant mice. **(A,B,C,D,E, F)** Bone marker RT-realtime PCR of calvariae from *Amel* (A) and *Ambn* (B) deficient mice, suture patency related gene (C,D), and calvarial osteoblasts from *Amel* (E) and *Ambn* (F) deficient mice. *Msx2* expression was reduced while *Alx4* expression showed different expression levels in calvariae from *Amel* (C) and *Ambn* (D) deficient mice. Note the significant reduction in bone marker and transcription factor gene expression levels, e.g. *Runx2*, *Sp7* and *Ibsp* in calvarial

osteoblasts after loss of *Amel* and *Ambn* (E,F). **(G)** *In vitro* mineralization assay of primary calvarial osteoblasts from *Amel* and *Ambn* deficient mice compared to those of wildtypes. * = $P < 0.05$.

REFERENCES

Addison WN, McKee MD (2010). ASARM mineralization hypothesis: a bridge to progress. *J Bone Miner Res* 25(5):1191-1192.

Deutsch D, Haze-Filderman A, Blumenfeld A, Dafni L, Leiser Y, Shay B *et al.* (2006). Amelogenin, a major structural protein in mineralizing enamel, is also expressed in soft tissues: brain and cells of the hematopoietic system. *European journal of oral sciences* 114 Suppl 1(183-189; discussion 201-182, 381.

Diekwisch T (2011). Evolution and ameloblastin. *European journal of oral sciences* 119 Suppl 1(293-297.

Fisher LW, McBride OW, Termine JD, Young MF (1990). Human bone sialoprotein. Deduced protein sequence and amino acid localization. *J. Biol. Chem.* 265(4):2347-2351.

Fong CD, Cerny R, Hammarstrom L, Slaby I (1998). Sequential expression of an amelin gene in mesenchymal and epithelial cells during odontogenesis in rats. *European journal of oral sciences* 106 Suppl 1(324-330.

Fukumoto S, Kiba T, Hall B, Iehara N, Nakamura T, Longenecker G *et al.* (2004). Ameloblastin is a cell adhesion molecule required for maintaining the differentiation state of ameloblasts. *J Cell Biol* 167(5):973-983.

Gibson CW, Yuan ZA, Hall B, Longenecker G, Chen E, Thyagarajan T *et al.* (2001). Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. *J Biol Chem* 276(34):31871-31875.

Hao J, He G, Narayanan K, Zou B, Lin L, Muni T *et al.* (2005). Identification of differentially expressed cDNA transcripts from a rat odontoblast cell line. *Bone* 37(4):578-588.

Hatakeyama J, Philp D, Hatakeyama Y, Haruyama N, Shum L, Aragon MA *et al.* (2006). Amelogenin-mediated regulation of osteoclastogenesis, and periodontal cell proliferation and migration. *J Dent Res* 85(2):144-149.

Haze A, Taylor AL, Blumenfeld A, Rosenfeld E, Leiser Y, Dafni L *et al.* (2007). Amelogenin expression in long bone and cartilage cells and in bone marrow progenitor cells. *Anat Rec (Hoboken)* 290(5):455-460.

Huang YC, Tanimoto K, Tanne Y, Kamiya T, Kunimatsu R, Michida M *et al.* (2010). Effects of human full-length amelogenin on the proliferation of human mesenchymal stem cells derived from bone marrow. *Cell Tissue Res* 342(2):205-212.

Huq NL, Cross KJ, Ung M, Reynolds EC (2005). A review of protein structure and gene organisation for proteins associated with mineralised tissue and calcium phosphate stabilisation encoded on human chromosome 4. *Arch Oral Biol* 50(7):599-609.

Iizuka S, Kudo Y, Yoshida M, Tsunematsu T, Yoshiko Y, Uchida T *et al.* (2011). Ameloblastin regulates osteogenic differentiation by inhibiting Src kinase via cross talk between integrin beta1 and CD63. *Mol Cell Biol* 31(4):783-792.

Inai T, Inai Y, Kurisu K (1993). Immunohistochemical detection of an enamel protein-related epitope in rat bone at an early stage of osteogenesis. *Histochemistry* 99(5):355-362.

Kawasaki K, Weiss KM (2008). SCPP gene evolution and the dental mineralization continuum. *J Dent Res* 87(6):520-531.

Li Y, Yuan ZA, Aragon MA, Kulkarni AB, Gibson CW (2006). Comparison of body weight and gene expression in amelogenin null and wild-type mice. *European journal of oral sciences* 114 Suppl 1(190-193; discussion 201-192, 381.

Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods* 25(4):402-408.

Lu X, Ito Y, Atsawasuwan P, Dangaria S, Yan X, Wu T, Evans CA, Luan X (2013). Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway. *Bone* 54(1):157-68

Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F *et al.* (2008). Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. *J Exp Med* 205(5):1145-1153.

Meredith RW, Gatesy J., Springer MS (2013). Molecular decay of enamel matrix protein genes in turtles and other edentulous amniotes. *BMC Evol Biol* doi: 10.1186/1471-2148-13-20.

Nunez J, Sanz M, Hoz-Rodriguez L, Zeichner-David M, Arzate H (2010). Human cementoblasts express enamel-associated molecules in vitro and in vivo. *J Periodontal Res* 45(6):809-814.

Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ (1992). Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. *J Bone Miner Res* 7(6):683-92.

Spahr A, Lyngstadaas SP, Slaby I, Haller B, Boeckh C, Tsoulfidou F *et al.* (2002). Expression of amelin and trauma-induced dentin formation. *Clin Oral Investig* 6(1):51-57.

Staines K, Macrae V, Farquharson C (2012). The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. *J Endocrinol*.

Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006). Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. *Endocrinology* 147(7):3613-3622.

Turner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A *et al.* (2010). Osteopontin deficiency increases bone fragility but preserves bone mass. *Bone* 46(6):1564-1573.

Ye L, Le TQ, Zhu L, Butcher K, Schneider RA, Li W *et al.* (2006). Amelogenins in human developing and mature dental pulp. *J Dent Res* 85(9):814-818.

Zeichner-David M, Chen LS, Hsu Z, Reyna J, Caton J, Bringas P (2006). Amelogenin and ameloblastin show growth-factor like activity in periodontal ligament cells. *European journal of oral sciences* 114 Suppl 1(244-253; discussion 254-246, 381-242.

Zhang Y, Zhang X, Lu X, Atsawasuwan P, Luan X (2011). Ameloblastin regulates cell attachment and proliferation through RhoA and p27. *European journal of oral sciences* 119 Suppl 1(280-285.